Portuguese Bluepharma invests EUR 30 M to produce oral ‎drugs ‎

Portuguese Bluepharma invests EUR 30 M to produce oral ‎drugs ‎- Portugal Business News

Portuguese pharmaceutical company Bluepharma has ‎invested EUR 30 million to produce potent oral drugs in solid ‎form in one of the largest industrial units in Europe.‎

Bluepharma, that is located in Coimbra in Central Portugal, ‎was the first Portuguese pharmaceutical company to be FDA ‎approved for export to the US market. The drugs produced in the new unit ‎will decrease dependence on Asian countries and will ensure that the supply ‎chain for critical medicines will be within EU borders.‎

With the recent scarcity of essential drugs, this new ‎production unit is strategic, with quality products to be ‎produced while being competitive on the international ‎market. Bluepharma will be producing potent drugs, ‎including in the field on oncology, and is expecting an annual ‎production of 300 million units for generics.‎

The pharmaceutical group, that is comprised of 20 ‎companies, exported more than 90% of its output to over 100 ‎multinationals in 40 countries in 2022. ‎

#pharmaceuticalinvestmentsportugal #pharmaceuticalsportugal #Bluepharma #genericsportugal #portugalnews #portugalbusinessnews